Adam Płużański

16.9k total citations · 2 hit papers
56 papers, 2.1k citations indexed

About

Adam Płużański is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Adam Płużański has authored 56 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 14 papers in Surgery. Recurrent topics in Adam Płużański's work include Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Adam Płużański is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Adam Płużański collaborates with scholars based in Poland, United States and Spain. Adam Płużański's co-authors include Tony Mok, Yi‐Long Wu, Ki Hyeong Lee, Kazuhiko Nakagawa, Rafael Rosell, Maria Rita Migliorino, J. Corral, Xiangdong Zhou, Seiji Niho and Ying Cheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Adam Płużański

53 papers receiving 2.0k citations

Hit Papers

Dacomitinib versus gefitinib as first-line treatment for ... 2017 2026 2020 2023 2017 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    2017 854 citations Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology profile →
  2. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
    2018 331 citations Tony Mok, Ying Cheng et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam Płużański Poland 15 1.7k 1.6k 473 319 102 56 2.1k
Puyuan Xing China 22 1.0k 0.6× 1.2k 0.7× 461 1.0× 295 0.9× 115 1.1× 149 1.7k
Fábio Franke United States 19 1.4k 0.8× 1.3k 0.8× 558 1.2× 535 1.7× 93 0.9× 54 2.0k
Daniel Haggstrom United States 8 1.5k 0.9× 1.2k 0.7× 691 1.5× 455 1.4× 63 0.6× 22 1.8k
Maximilian J. Hochmair Austria 27 2.1k 1.3× 2.2k 1.4× 731 1.5× 607 1.9× 142 1.4× 215 2.9k
Shang‐Gin Wu Taiwan 29 1.9k 1.1× 1.5k 0.9× 955 2.0× 683 2.1× 178 1.7× 64 2.6k
Xiuyu Julie Cong United States 13 1.3k 0.8× 1.2k 0.8× 563 1.2× 189 0.6× 112 1.1× 19 1.7k
Erzsébet Juhász Hungary 15 1.1k 0.6× 1.2k 0.7× 568 1.2× 235 0.7× 71 0.7× 28 1.7k
Kathryn H. Brown United Kingdom 15 1.8k 1.0× 1.4k 0.9× 931 2.0× 460 1.4× 85 0.8× 30 2.4k
Felice Mucilli Italy 16 1.5k 0.9× 1.1k 0.7× 756 1.6× 464 1.5× 183 1.8× 59 2.0k

Countries citing papers authored by Adam Płużański

Since Specialization
Citations

This map shows the geographic impact of Adam Płużański's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Płużański with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Płużański more than expected).

Fields of papers citing papers by Adam Płużański

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Płużański. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Płużański. The network helps show where Adam Płużański may publish in the future.

Co-authorship network of co-authors of Adam Płużański

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Płużański. A scholar is included among the top collaborators of Adam Płużański based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Płużański. Adam Płużański is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Płużański, Adam, et al.. (2024). Clinicopathological characteristics of patients with primary tracheal tumors: Analysis of eighty‐nine cases. Thoracic Cancer. 15(11). 878–883. 5 indexed citations
3.
Płużański, Adam, et al.. (2024). Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 12(8). 181–181. 1 indexed citations
4.
Pu, Xingxiang, Juan Li, Bo Zhang, et al.. (2024). Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncology. 20(37). 2971–2982. 2 indexed citations
5.
Shalata, Walid, Waleed Kian, Rafał Dziadziuszko, et al.. (2024). Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study). Current Oncology. 31(8). 4369–4381. 1 indexed citations
6.
Płużański, Adam, et al.. (2024). Tracheal Tumors: Clinical Practice Guidelines for Palliative Treatment and Follow-Up. Oncology Reviews. 18. 1451247–1451247.
7.
8.
9.
Płużański, Adam, et al.. (2023). Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. Journal of Clinical Medicine. 12(6). 2409–2409. 2 indexed citations
10.
Borghaei, Hossein, Kenneth J. O’Byrne, Luis Paz‐Ares, et al.. (2023). Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO Open. 8(6). 102065–102065. 23 indexed citations
11.
12.
Płużański, Adam, et al.. (2022). Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. Current Oncology. 30(1). 462–475. 4 indexed citations
13.
Płużański, Adam, et al.. (2022). Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors. Cancers. 14(7). 1665–1665. 7 indexed citations
14.
Ciuleanu, Tudor–Eliade, Adam Płużański, J.-S. Lee, et al.. (2021). OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1. Journal of Thoracic Oncology. 16(1). S2–S3. 2 indexed citations
15.
Agbarya, Abed, Alfredo Addeo, Kristof Cuppens, et al.. (2020). 1683P SARS-CoV-2 infection and lung cancer management in Europe. Annals of Oncology. 31. S996–S997. 2 indexed citations
16.
Kowalski, Dariusz M., Adam Płużański, Małgorzata Szołkowska, et al.. (2019). Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome. Polish Journal of Cardio-Thoracic Surgery. 16(1). 49–51. 2 indexed citations
17.
Mok, Tony, Ying Cheng, Xiangdong Zhou, et al.. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology. 36(22). 2244–2250. 331 indexed citations breakdown →
18.
Mok, Tony, Kazuhiko Nakagawa, Rafael Rosell, et al.. (2018). MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S454–S454. 5 indexed citations
19.
Wu, Yi‐Long, Ying Cheng, Xiangdong Zhou, et al.. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 18(11). 1454–1466. 854 indexed citations breakdown →
20.
Płużański, Adam, et al.. (2016). Prevention of chemotherapy-induced nausea and vomiting — standards versus clinical practice. Oncology in Clinical Practice. 12(4). 153–157. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Puyuan Xing Breakdown of academic impact, for papers by Fábio Franke Breakdown of academic impact, for papers by Daniel Haggstrom Breakdown of academic impact, for papers by Maximilian J. Hochmair Breakdown of academic impact, for papers by Shang‐Gin Wu Breakdown of academic impact, for papers by Xiuyu Julie Cong Breakdown of academic impact, for papers by Erzsébet Juhász Breakdown of academic impact, for papers by Kathryn H. Brown Breakdown of academic impact, for papers by Felice Mucilli
Rankless by CCL
2026